Key points are not available for this paper at this time.
Three-month outcomes of patients receiving low-dose intravenous recombinant tissue plasminogen activator therapy in the present study were similar to those from postmarketing surveys using 0.9 mg/kg alteplase.
Toyoda et al. (Fri,) studied this question.